Arterys sought FDA clearance for Oncology AI suite

Arterys Inc declared its fifth 510 (k) clearance for Arterys Oncology AI suite and is milestone indicative of the company’s momentum in applying AI to further medical imaging accuracy and consistency.

The new oncology software complements Arterys’ existing web-based offering, and helps clinicians measure and track tumors or potential cancers, and easily apply radiological standards. The initial deep learning workflows will be for liver MRI and CT scans as well as for lungCT scans.

Source: Arterys

Radiologist and Arterys co-founder Albert Hsiao, M.D., Ph.D said “We desperately need more efficient technology to automatically track lung and liver lesions to further improve diagnosis, assess response to treatment, and automate reporting with standardized terminology including Lung-RADS and LI-RADS. The Oncology Lung AI and Liver AI products are designed to maximize efficiency and accuracy of the radiologist read and will power next-generation radiology interpretation.”

Oncology AI suite runs on the Arterys MICA (Medical Imaging Cloud AI) platform, which is easier to deploy than on-premise imaging systems and complies with patient data privacy and security requirements in 27 countries, including the US, Canada, all of EuropeAustralia, and New Zealand.

Arterys CEO Fabien Beckers, Ph.D said “A core Arterys mission is to help the medical community identify cancer earlier, so that patients can receive optimal treatment and improved prognosis. FDA clearance of our Oncology AI suite will help clinicians to quickly measure and track tumors over time. Additionally, our software enables seamless collaboration for clinicians, so second opinions can be easily gathered from within the hospital, or from outside experts.”

 

Comments (0)
Add Comment